Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Treatment Of Gastrointestinal Bleeding With PuraStat
DRKS00012480Phase 4Recruiting
- Sponsor
- Charité – Universitätsmedizin Berlin
- Start
- Jul 2017
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of PuraStat in gastrointestinal bleeding, Peptic ulcer disease (PUD), reflux oesophagitis and 1 more, sponsored by Charité – Universitätsmedizin Berlin. Primary endpoint: Hemostatic efficacy of PuraStat. Started Jul 2017; status: recruiting.
02
Drugs
PuraStat
03
Conditions
gastrointestinal bleedingPeptic ulcer disease (PUD)reflux oesophagitisirritable bowel syndrome (IBS)
Beyond the preview
Go deeper on DRKS00012480.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on DRKS00012480.